Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02099604
Recruitment Status : Withdrawn (Study objectives were considered as obsolete regarding the new AAD arrival)
First Posted : March 31, 2014
Last Update Posted : July 12, 2017
Sponsor:
Collaborator:
Institut Pasteur
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Brief Summary:
The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the sustained virological response (SVR) at 3 months after end of treatment (week 60).

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Drug: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin Phase 3

Detailed Description:

- Method: Phase III, randomized, open-label superiority clinical trial, among Egyptian patients with chronic hepatitis C.

- Treatment strategy: Vitamin D Arm: Vitamin D over a 4 weeks lead-in phase followed by Vitamin D in combination with PEG-INF plus RBV during 48 weeks. Standard of Care Arm: PEG-INF plus RBV during 48 weeks.

- Main outcome: Proportion of patients with Sustained Virological Response (SVR) as defined by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping treatment.

  • Sample Size: 520 patients (260 per arm)
  • Enrollment period: 12 months
  • Patient's participation duration: 62 weeks (SOC Arm), 66 weeks (Vit-D Arm)
  • Statistical analysis:

The superiority of the vitamin D arm will be tested against the standard PEG IFN + RBV combination. 260 patients in each arm will give 80% power to document a 12% difference in the SVR rates between the experimental (Vitamin D) and the control (standard treatment) arms..

A futility analysis is planned for this study, in order to be able to interrupt the trial prematurely in case preliminary results show a lack of efficacy of vitamin D.

This analysis will be performed on half of the patients, thus 260 patients (130 patients per arm), on a week 12/14 week criterion (HCV RNA viral load at W12/W14).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial
Study Start Date : April 2014
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014


Arm Intervention/treatment
Experimental: Vitamin D
Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
Drug: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
Other Names:
  • Vidrop
  • PegIntron
  • Rebetol

No Intervention: Standard of Care
Pegylated Interferon Alpha 2b + Ribavirin



Primary Outcome Measures :
  1. Proportion of patients with Sustained Virological Response (SVR). [ Time Frame: 60 Weeks after peg-IFN/RBV initiation ]
    Proportion of patients with Sustained Virological Response (SVR) as defined by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping treatment.


Secondary Outcome Measures :
  1. Rapid Virological Response (RVR) [ Time Frame: 4 Weeks after peg-IFN/RBV initiation ]
    HCV RNA at 4 weeks post initiation of combination therapy (PEG IFN + RBV)

  2. Early Virological Response (EVR) [ Time Frame: 12 Weeks after peg-IFN/RBV initiation ]
    HCV RNA at 12 weeks post initiation of combination therapy

  3. End of Treatment Response (ETR) [ Time Frame: 48 Weeks after peg-IFN/RBV initiation ]
    HCV RNA at end of treatment (week 48)

  4. Normalization of ALT during treatment and 12 weeks after the end of treatment [ Time Frame: From 2 Weeks after peg-IFN/RBV initiation to End of Follow-up (Week 60) ]
  5. Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale) [ Time Frame: From Lead-in phase (Week -4) to End of Follow-up (Week 60) ]
    incidence of SAE leading to dosage reduction or treatment cessation, percentage of patients treated by EPO and G-CSF

  6. Evolution of FibroScan values between pre-inclusion and week 60 [ Time Frame: At Screening Visit 2 (S2) and at End of Follow-up (Week 60) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Common with National Program for Viral Hepatitis

  • Age: 18 years to 60 years
  • Positive HCV antibodies using a third generation test
  • Detectable HCV RNA by PCR
  • Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated liver enzymes or scores F2/F3
  • Naïve to treatment with PEG-IFN and RBV
  • HBs antigen negative
  • Prothrombin time ≥60 %, normal bilirubin, alpha-foeto protein < 3*normal range of the laboratory, anti-nuclear antibodies<1/160 Effective contraception during the treatment period; no breast-feeding

Specific to the trial

  • Prior approval from the Ministry of Health to be treated as part of the National Program with allocation to Peg-IFN α2b treatment
  • Living <100 km from Cairo and able to come to the centre every week for the treatment
  • Signed informed consent and willingness to participate in the trial
  • Naïve to treatment with vitamin D (received vitamin D less than 30 consecutive days in the 3 months preceding inclusion)
  • Biopsy slide validated by NHTMRI pathologist

Exclusion Criteria:

Common with National program for Viral Hepatitis

  • Serious co-morbid conditions such as severe hypertension, heart failure, significant coronary heart disease, poorly controlled diabetes (HbA1C>8%) , chronic obstructive pulmonary disease
  • Major uncontrolled depressive illness
  • Solid transplant organ (renal, heart, or lung)
  • Untreated thyroid disease
  • History of previous anti-HCV therapy
  • Body mass index (BMI) greater than 30 kg/m²
  • Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be proposed or done, patients with known HIV coinfection will not be included in the trial
  • Anti-HCV therapy contraindications:
  • hypersensitivity to one of the two drugs (PEG-IFN, RBV)
  • pregnancy or unwilling to comply with adequate contraception
  • breast-feeding
  • neutropenia (<1500/mm3)
  • anaemia (<11g/dL for women ; <12g/dL for men)
  • thrombocytopenia (<100,000/mm3)
  • elevated creatinin (>1.5mg/dL)
  • concomitant liver disease other than hepatitis C (immuno-active chronic hepatitis B, autoimmune hepatitis, alcoholic liver disease, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson disease)
  • liver biopsy showing severe steatosis (>66%) and steatohepatitis; decompensated cirrhosis (Child Pugh>A); hepatocellular carcinoma, METAVIR score F4.
  • TSH>5 mU/L

Specific to the trial

  • Patients allocated to Peg-IFN alpha 2a treatment
  • Hypersensitivity to vitamin D
  • Vitamin D contraindications:
  • hypercalcaemia (fasting calcaemia >105 mg/L or 2.62 mmol/L)
  • ratio calciuria / creatininuria (fasting ratio >1 mmol Ca/mmol creatinin)
  • hyperphosphatemia (>1.5 mmol/L)
  • calcium lithiasis
  • patients being treated with thiazide diuretics (risk of hypercalcaemia with vitamin D treatment)
  • patients being treated with glucocorticoïds (decrease in vitamin D efficacy)
  • postmenopausal women treated by vitamin D and calcium for osteoporosis
  • Treatment by vitamin D more than 30 consecutive days in the 3 months preceding inclusion in the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02099604


Locations
Layout table for location information
Egypt
NHTMRI
Cairo, Egypt
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Institut Pasteur
Investigators
Layout table for investigator information
Study Chair: Gamal Esmat, MD, PhD NHTMRI, Cairo, Egypt
Study Chair: Arnaud Fontanet, MD, PhD Institut Pasteur, Paris France

Layout table for additonal information
Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier: NCT02099604     History of Changes
Other Study ID Numbers: ANRS 12226 ViZIR
First Posted: March 31, 2014    Key Record Dates
Last Update Posted: July 12, 2017
Last Verified: July 2017
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Hepatitis C - Genotype 4
SVR (Sustained Virological Response)
Vitamin D
Treatment Naïve
Additional relevant MeSH terms:
Layout table for MeSH terms
Ribavirin
Interferon-alpha
Interferon alpha-2
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Vitamin D
Ergocalciferols
Vitamins
Interferons
Peginterferon alfa-2b
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents